Prelude PRT2527

Hematological neoplasms
Myelodysplastic Syndrome (MDS), Acute myeloid leukemia
other systemic therapies
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies.
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies.